Jenny L. Byrne

Hucknall Road
Nottingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T cell depleted Matched Unrelated Donor Haematopoietic Cell Transplantation.

Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T cell depleted Matched Unrelated Donor Haematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: June 16, 2026

Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemia.

Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemia.

Journal: British journal of haematology

Published: November 21, 2025

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

Journal: Bone marrow transplantation

Published: November 19, 2025

Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.

Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.

Journal: Haematologica

Published: December 18, 2024

A comparison of cryopreserved and noncryopreserved peripheral blood hematopoietic stem cells for autologous transplantation in multiple myeloma: a study from the chronic malignancies working party of the EBMT.

A comparison of cryopreserved and noncryopreserved peripheral blood hematopoietic stem cells for autologous transplantation in multiple myeloma: a study from the chronic malignancies working party of the EBMT.

Journal: Cytotherapy

Published: November 14, 2024

Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma.

Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma.

Journal: Blood cancer discovery

Published: July 14, 2024

Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Journal: American journal of hematology

Published: June 26, 2024

Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy.

Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy.

Journal: British journal of haematology

Published: March 27, 2024

Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT.

Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT.

Journal: British journal of haematology

Published: January 13, 2024

Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.

Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.

Journal: Bone marrow transplantation

Published: November 23, 2023

Capture-based targeted sequencing using a T-cell control in myeloid malignancies and idiopathic cytopenias.

Capture-based targeted sequencing using a T-cell control in myeloid malignancies and idiopathic cytopenias.

Journal: British journal of haematology

Published: November 21, 2023

Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT).

Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT).

Journal: Transplantation and cellular therapy

Published: July 11, 2023

Showing 1-12 of 57

Last Updated: 09/26/2026